Valneva Austria Gmbh

This study looks at how well the VLA1553 vaccine prevents chikungunya disease in Brazil. Researchers will compare vaccinated and unvaccinated people who have chikungunya-like symptoms. The goal is to see if the vaccine reduces infections in a real-world setting. About 1,200 adult…

This study looks at how long the chikungunya vaccine (VLA1553) keeps protecting adults and whether it stays safe over time. It involves 363 adults who already got the vaccine in an earlier trial. Researchers will measure antibody levels and watch for any serious side effects.

This study was designed to test a chikungunya vaccine (VLA1553) in healthy children aged 1 to 11 years. The goal was to see if the vaccine triggers a strong immune response and is safe compared to a standard vaccine. However, the trial was withdrawn before any participants were e…

This study is checking the safety of a new vaccine called VLA1553 that protects against chikungunya, a virus spread by mosquitoes. Researchers will follow 5000 people who got the vaccine to see how often side effects like arthritis or heart problems happen. The goal is to make su…

This study tests over 5,300 people in about 10 Brazilian towns to see how many have already been infected with chikungunya virus before a new vaccine (VLA1553) is offered. Participants are aged 2 and older who live in selected households. The goal is to understand how past infect…